TJ-L1IF

N/A

Report date: 2026/01/29 14:35:47

Base Information

Drug NameTJ-L1IF

Drug Alias NamePD-L1 Checkpoint Inhibitor/IFN Alpha 2b Prodrug (I-Mab Biopharma/Shanghai Affinity Biopharmaceutical Technology)TJ-L1IF

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate +[4]

Mechanisms of ActionInterferon alpha 2 ligandProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Interferon alpha-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesI-Mab Bio-Tech (Tianjin) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesI-Mab Bio-Tech (Tianjin) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A